Health Care/Hospital

WELLlife COVID-19/Influenza A&B Home Test on Sale for Amazon Prime Day

Standfirst: Welllife, a Flu home test in addition to COVID-19 BOLINGBROOK, Ill., Oct. 3, 2024 /PRNewswire/ -- WELLlife, a leading innovator in medical diagnostic and testing solutions, is increasing accessibility to respiratory illness testing this flu season. The WELLlife COVID-19/Influenza A&B...

2024-10-03 21:00 1174

The Exosome Production Method Patent by Panacell Biotech Registered as Original Technology

SEOUL, South Korea, Oct. 3, 2024 /PRNewswire/ -- Panacell Biotech Co., Ltd. (Panacell Biotech) announced that the patent related to their exosome manufacturing method filed last year was registered as a core technology in the patent registry onAugust 7, 2024, following the Patent Act. Panacell B...

2024-10-03 20:00 1692

South Korea's SK bioscience Completes Acquisition of Germany's CDMO IDT Biologika

* SK bioscience completed the acquisition of German CDMO company IDT Biologika with over a century of history that enables immediate expansion in revenue and infrastructure. * The company aims to double sales of IDT Biologika by 2028 through new business projects and operational efficiency. ...

2024-10-02 20:00 1966

Zepp Regains Compliance with NYSE Minimum Price Continued Listing Criterion

MILPITAS, Calif., Oct. 2, 2024 /PRNewswire/ -- Zepp Health Corporation ("Zepp Health" or the "Company") (NYSE: ZEPP), a global leader in smart wearables and health technology, today announced that it has received a letter from the New York Stock Exchange ("NYSE") datedOctober 2, 2024 (the "Octobe...

2024-10-02 19:00 4000

Baird Medical and ExcelFin Acquisition Corp Complete Business Combination

NEW YORK, Oct. 1, 2024 /PRNewswire/ -- Betters Medical Investment Holdings Limited ("Baird Medical" or the "Company"), a leading microwave ablation ("MWA") medical device developer and provider inChina (which has recently expanded into the U.S. market following its receipt of US FDA 510(k) clear...

2024-10-02 05:37 3711

PeptiGrowth Inc. is Launching a Novel Synthetic FGF2 Alternative Peptide (FGFR1c Agonist)

TOKYO, Oct. 1, 2024 /PRNewswire/ -- PeptiGrowth Inc. (Headquarters: Chiyoda-ku, Tokyo; President: Jiro Sugimoto) has successfully developed a novel synthetic peptide called "FGF2 alternative peptide (FGFR1c agonist)", which has equivalent function to recombinant FGF2 (Fibroblast Growth Factor 2, ...

2024-10-01 21:00 1444

Digital & Intelligent Pathway: Xiaohongshu and VOGUE Business Unveil Groundbreaking Lifestyle Marketing Insights at Milan Summit

MILAN, Sept. 30, 2024 /PRNewswire/ -- As the exclusive strategic partner, Xiaohongshu teamed up with VOGUE Business to host theThe Digital Silk Road: Pioneering the Future of Luxury Lifestyles summit at Milan's historic Palazzo Serbelloni onSeptember 26-27, 2024. The event aimed to redefine marke...

2024-09-30 16:50 1587

Xiaohongshu x VOGUE Business Unveils New Horizons in Healthcare and Wellness at Milan Summit

MILAN, Sept. 30, 2024 /PRNewswire/ -- From September 26 to 27, Xiaohongshu partnered with VOGUE Business to host theDigital Silk Road: Pioneering the Future of Luxury Lifestyle summit in Milan, Italy. As the exclusive strategic partner, Xiaohongshu gathered global industry leaders on the internat...

2024-09-30 16:30 1270

NUS researchers develop revolutionary technology to unravel complex protein interactions that could transform cancer diagnostics

Scalable and adaptable, TETRIS captures the diversity of protein interactions on site to inform accurate cancer diagnoses, enabling the personalisation of ensuing treatments. SINGAPORE, Sept. 30, 2024 /PRNewswire/ -- A team of researchers from the National University of Singapore's

2024-09-30 15:51 1359

Doer Biologics Announces First Patient Dosed in Phase 2 Study of DR10624 for Treatment of Severe Hypertriglyceridemia

HANGZHOU, China, Sept. 30, 2024 /PRNewswire/ -- Zhejiang Doer Biologics Co., Ltd. ("Doer Bio"), a clinical stage biopharmaceutical company developing innovative biotherapeutics for metabolic diseases and cancers, today announces that DR10624, its first-in-class (FIC), tri-specific agonist targeti...

2024-09-30 15:00 1063

IASO Bio Scientist and Leading Chinese Physicians in Onco-Hematology Visit Hematology Center at the State University of Campinas, Brazil, to Explore Cooperation in Cancer Treatment

SHANGHAI and NANJING, China and SAN JOSE, Calif., Sept. 30, 2024 /PRNewswire/ -- OnSeptember 23, in Rio de Janeiro, on the eve of the International Myeloma Society (IMS) Annual Meeting, Dr.Yongke Zhang, Chief Scientific Officer of IASO Biotherapeutics (IASO Bio), along with leading Chinese onco-h...

2024-09-30 13:48 1000

Akeso's Cadonilimab Receives Second Indication Approval from NMPA for First-Line Treatment of Gastric/GEJ Cancer in All-Comers Population

HONG KONG, Sept. 30, 2024 /PRNewswire/ -- September 30, 2024, Akeso (9926. HK) announced that its internally developed PD-1/CTLA-4 bispecific antibody, cadonilimab, has received approval from the National Medical Products Administration (NMPA) for a new indication: cadonilimab in combination with...

2024-09-30 13:42 990

World's First Carbon Neutral Salad: The Revolutionary Drinkable Salad that's Good for You and the Planet

HONG KONG, Sept. 29, 2024 /PRNewswire/ -- Tired of sacrificing taste for nutrition? Try Future Salad, the world's first carbon-neutral drinkable salad. It supports a healthy lifestyle and combats climate change. InSeptember 2024, on its 4th anniversary, Future Salad completed a Series A funding r...

2024-09-30 13:22 1551

Regor Enters into a Definitive Purchase Agreement for Genentech to Acquire Regor's Portfolio of next-generation CDK inhibitors for the Treatment of Breast Cancer

* Genentech will acquire Regor's next-generation CDK inhibitors for an upfront payment of$850 million in cash. Regor is also eligible to receive additional cash payments contingent on achieving future development, regulatory and commercial milestones CAMBRIDGE, Mass., Sept. 30, 2024 /PRNewswire...

2024-09-30 13:00 922

SeromYx Systems and ACROBiosystems Announce Strategic Collaboration on Comprehensive Functional Profiling of Anti-CD20 Monoclonal Antibodies

NEWARK, Del., Sept. 29, 2024 /PRNewswire/ -- SeromYx Systems, a cutting-edge immunology technology company, and ACROBiosystems, an innovative provider for life science solutions and tools, are excited to announce the release of their joint study on the comprehensive functional profiling of approv...

2024-09-29 21:00 1266

IASO Bio Presented Comparative Clinical Outcomes on the Optimal Lymphodepletion Prior to Infution of Equecabtagene Autoleucel(FucasoTM)in Patients with Relapsed Refractory Multiple Myeloma at 2024 IMS Annual Meeting

SHANGHAI and NANJING, China and SAN JOSE, Calif, Sept. 29, 2024 /PRNewswire/ -- IASO Biotherapeutics ("IASO Bio"), a biopharmaceutical company dedicated to discovering, developing, manufacturing and commercializing innovative cell therapy and antibody products, today announced a poster presentati...

2024-09-29 21:00 2210

New Beginnings, New Journey | Sanyou Opening of New 10,000-sqm Facility, Ushering in a New Era of Innovation for Bio Drugs

SHANGHAI, Sept. 28, 2024 /PRNewswire/ -- Sanyou Bio recently celebrated a prestigious move into its new 10,000-square-meter R&D building atShanghai headquarters. This is not just a change in physical location, but a qualitative leap in the company infrastructure. It marks a solid step forward for...

2024-09-28 20:00 2934

111, Inc. Announces Receipt of Notification from Nasdaq

SHANGHAI, Sept. 27, 2024 /PRNewswire/ -- 111, Inc. ("111" or the "Company") (NASDAQ: YI), a leading tech-enabled healthcare platform company committed to reshaping the value chain of healthcare industry by digitally empowering the upstream and downstream inChina, today announced it has received a...

2024-09-28 05:00 2902

Ping An Healthcare and Technology Stock Soared 10% - Managed Care Takes Center Stage in Corporate Health Management

SHANGHAI, Sept. 27, 2024 /PRNewswire/ -- On September 26, 2024, Ping An Healthcare and Technology Company Limited ("Ping An Good Doctor", "Ping An Health", or "the Company", Stock Code: 1833.HK),China's leading healthcare ecosystem platform, saw its share price surge by nearly 10% during the trad...

2024-09-27 21:12 5610

Concord Medical Reports Financial Results for the First Half of 2024

BEIJING, Sept. 27, 2024 /PRNewswire/ -- Concord Medical Services Holdings Limited ("Concord Medical" or the "Company") (NYSE: CCM), a healthcare provider specialized in cancer treatment, research, education and prevention inChina, today announced its unaudited consolidated financial results for t...

2024-09-27 19:00 4030
1 ... 9101112131415 ... 277